Impact of CBCT frequency on target coverage and dose to the organs at risk in adjuvant breast cancer radiotherapy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 08 2021
30 08 2021
Historique:
received:
23
04
2021
accepted:
17
08
2021
entrez:
31
8
2021
pubmed:
1
9
2021
medline:
10
11
2021
Statut:
epublish
Résumé
The current study aims to assess the effect of cone beam computed tomography (CBCT) frequency during adjuvant breast cancer radiotherapy with simultaneous integrated boost (SIB) on target volume coverage and dose to the organs at risk (OAR). 50 breast cancer patients receiving either non-hypofractionated or hypofractionated radiotherapy after lumpectomy including a SIB to the tumor bed were selected for this study. All patients were treated in volumetric modulated arc therapy (VMAT) technique and underwent daily CBCT imaging. In order to estimate the delivered dose during the treatment, the applied fraction doses were recalculated on daily CBCT scans and accumulated using deformable image registration. Based on a total of 2440 dose recalculations, dose coverage in the clinical target volumes (CTV) and OAR was compared depending on the CBCT frequency. The estimated delivered dose (V95%) for breast-CTV and SIB-CTV was significantly lower than the planned dose distribution, irrespective of the CBCT-frequency. Between daily CBCT and CBCT on alternate days, no significant dose differences were found regarding V95% for both, breast-CTV and SIB-CTV. Dose distribution in the OAR was similar for both imaging protocols. Weekly CBCT though led to a significant decrease in dose coverage compared to daily CBCT and a small but significant dose increase in most OAR. Daily CBCT imaging might not be necessary to ensure adequate dose coverage in the target volumes while efficiently sparing the OAR during adjuvant breast cancer radiotherapy with SIB.
Identifiants
pubmed: 34462489
doi: 10.1038/s41598-021-96836-0
pii: 10.1038/s41598-021-96836-0
pmc: PMC8405651
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17378Informations de copyright
© 2021. The Author(s).
Références
Strahlenther Onkol. 2021 Sep;197(9):802-811
pubmed: 33320286
Cancer Med. 2018 Aug;7(8):3622-3629
pubmed: 29968974
Rep Pract Oncol Radiother. 2018 Jan-Feb;23(1):61-67
pubmed: 29379398
Radiother Oncol. 2016 Jan;118(1):205-8
pubmed: 26791404
Lancet. 2019 Dec 14;394(10215):2165-2172
pubmed: 31813635
Front Oncol. 2014 Sep 23;4:257
pubmed: 25295227
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):574-582
pubmed: 30118822
Health Phys. 2013 May;104(5):499-503
pubmed: 23532078
Phys Med Biol. 2018 Aug 01;63(15):155014
pubmed: 29978832
Phys Med Biol. 2007 Feb 7;52(3):685-705
pubmed: 17228114
J Radiat Res. 2020 Sep 8;61(5):747-754
pubmed: 32785596
Br J Radiol. 2012 Nov;85(1019):e1051-7
pubmed: 22553296
J Med Radiat Sci. 2016 Dec;63(4):224-231
pubmed: 27741383
Phys Med. 2015 Nov;31(7):647-58
pubmed: 26148865
Am J Clin Oncol. 2020 Jul;43(7):459-468
pubmed: 32452841
Australas Phys Eng Sci Med. 2017 Jun;40(2):305-315
pubmed: 28243923
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1235-43
pubmed: 20472368
Strahlenther Onkol. 2020 Jan;196(1):15-22
pubmed: 31722060
Breast. 2018 Dec;42:31-37
pubmed: 30149235
Med Dosim. 2016 Autumn;41(3):225-9
pubmed: 27311516
Breast Care (Basel). 2015 Feb;10(1):44-9
pubmed: 25960725
Br J Radiol. 2019 Apr;92(1096):20180383
pubmed: 30433821
J Appl Clin Med Phys. 2019 Mar;20(3):97-104
pubmed: 30861276
Med Phys. 2014 Mar;41(3):031703
pubmed: 24593707
Med Dosim. 2014 Summer;39(2):190-3
pubmed: 24630912
Breast Care (Basel). 2015 Aug;10(4):240-5
pubmed: 26600759
Radiat Oncol. 2018 Sep 5;13(1):168
pubmed: 30185206
Oncotarget. 2017 Mar 21;8(12):20179-20186
pubmed: 28423624